1. Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients.
- Author
-
Brier MR, Schindler SE, Salter A, Perantie D, Shelley N, Judge B, Keefe S, Kirmess KM, Verghese PB, Yarasheski KE, Venkatesh V, Raji CA, Gordon BA, Bateman RJ, Morris JC, Naismith RT, Holtzman DM, Benzinger TLS, and Cross AH
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Alzheimer Disease pathology, Alzheimer Disease metabolism, Alzheimer Disease blood, Biomarkers blood, Aged, Amyloid beta-Peptides metabolism, Amyloid beta-Peptides blood, Multiple Sclerosis pathology, Multiple Sclerosis blood
- Abstract
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459., (© 2024 American Neurological Association.)
- Published
- 2024
- Full Text
- View/download PDF